Therefore, we speculate that BV, as an ADC drug targeting CD30, can also play an anticancer role by specifically binding to CD30 on the surface of tumor cells and inhibiting the NF-κB and MAPK signaling pathways, but there are few relevant studies, and further basic research is needed to validate this in the future. This evidence concerns the gene NFKB1 and neoplasm.